はじめての方へショーケース価格
  1. 米国企業
  2. Coherus BioSciences, Inc.

Coherus BioSciences, Inc.CHRS

時価総額
$2.4億
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2014年
12月31日		2015年
12月31日		2016年
12月31日		2017年
12月31日		2018年
12月31日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日
Profit Loss-87-224-128-238-20990132-287-292
Depreciation and amortization-23333334
Share Based Compensation111727333534385151
Write-off of prepaid manufacturing services related to the termination of CHS-2020--------3-
Inventory Write Down-----0-526
Amortization Of Debt Discount Premium--1112346
Upfront and option payments to Junshi Biosciences------813635
Loss on debt extinguishment2--------6
Other Noncash Adjustments------012
Trade receivables, net-----14215-34-13
Inventory----54836647
Prepaid manufacturing1514-3-16-7111-44
Other prepaid, current and non-current assets-----20513
Accounts payable-----10-101-5
Accrued rebates, fees and reserves-----5130-3-25
Accrued compensation----8106-01
Accrued and other current and non-current liabilities-----105181
Net cash (used in) provided by operating activities-----15928154-37-241
Purchases of property and equipment367512712
Proceeds from Sale of Machinery and Equipment------0--
Purchases of investments in marketable securities---744320274182127
Proceeds From Sale And Maturity Of Marketable Securities---754320274100-
Proceeds from Sale of Marketable Securities-------82-
Upfront and option payments to Junshi Biosciences--------35
Other upfront and milestone based license fee payments-----1181362
Net cash used in investing activities-----1-13-14-138-167
Proceeds From Convertible Debt--75---222--
Proceeds from Issuance of Debt--------241
Proceeds From Issuance Of Common Stock-------41-
Proceeds from Issuance Initial Public Offering85-------6
Proceeds From Stock Options Exercised01302617101
Proceeds From Stock Plans----24432
Purchase of capped call options related to 2026 Convertible Notes------18--
Taxes paid related to net share settlement of RSUs-----1124
Repayment of 2022 Convertible Notes and premiums--------109
Repayment of 2025 Term Loan, premiums and exit fees--------82
Other financing activities---------1
Net cash provided by financing activities----105892245254
Net (decrease) increase in cash, cash equivalents and restricted cash-----55105364-124-354
Interest Paid Net----815171935
Income Taxes Paid------410
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-----510-
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability------203
Purchase of property and equipment in accounts payable and accrued liabilities------000
Non Cash Bonus Payment Settled In Common Stock---3--1--